It recorded a net loss of $7.0 million. Diluted earnings per share were -$0.21. Over the twelve months ended Sep 30, 2014, revenue was $1.0 million and the net loss was $5.0 million.
USD in millions, except per-share amounts and margins. The percent under a figure is the change from the year before.
| Line |
FY 2014
Sep 30, 2014
|
FY 2025
Dec 31, 2025
|
FY 2024
Dec 31, 2024
|
FY 2023
Dec 31, 2023
|
FY 2017
Dec 31, 2017
|
FY 2016
Dec 31, 2016
|
FY 2015
Dec 31, 2015
|
FY 2014
Dec 31, 2014
|
FY 2013
Dec 31, 2013
|
FY 2012
Dec 31, 2012
|
FY 2011
Dec 31, 2011
|
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
1
-1.6%
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
1
-9.6%
|
1
-11.1%
|
1
|
| Gross profit |
—
|
0
-75.5%
|
—
|
0
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
| Selling, general and administrative |
2
+98.3%
|
2
+107.5%
|
1
-58.5%
|
2
|
6
+1.1%
|
6
-22.5%
|
7
+193.5%
|
2
+42.8%
|
2
+29.7%
|
1
+65.2%
|
1
|
| Operating income |
-1
-764.4%
|
-3
-107.2%
|
-1
+46.5%
|
-2
|
-4
-3257.9%
|
0
+107.2%
|
-2
-25.4%
|
-2
-57.8%
|
-1
-252.2%
|
-0
+95.6%
|
-6
|
| Other income (expense) |
-4
-241.6%
|
-4
-75.4%
|
-2
+57.5%
|
-6
|
0
-99.8%
|
9
+818.8%
|
-1
-34.2%
|
-1
+74.6%
|
-4
-502.2%
|
-1
-152.2%
|
-0
|
| Pretax income |
-5
-496.9%
|
-7
-86.3%
|
-4
+54.3%
|
-8
|
-4
-147.4%
|
9
+389.2%
|
-3
-28.7%
|
-2
+47.1%
|
-5
-424.8%
|
-1
+86.3%
|
-7
|
| Income tax |
0
|
—
|
0
|
—
|
—
|
—
|
0
|
0
|
0
+100.0%
|
-0
-290.5%
|
-0
|
| Net income |
-5
-496.9%
|
-7
-80.9%
|
-4
+52.9%
|
-8
|
4
-57.6%
|
9
+368.1%
|
-3
-37.4%
|
-2
+47.1%
|
-5
-438.6%
|
-1
+86.7%
|
-7
|
| Net income to common |
—
|
-7
-79.0%
|
-4
+52.3%
|
-8
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
| Basic EPS |
—
|
—
|
-0.12
+52.0%
|
-0.25
|
-0.15
-139.5%
|
0.38
+323.5%
|
-0.17
+0.0%
|
-0.17
+51.4%
|
-0.35
-400.0%
|
-0.07
+86.8%
|
-0.53
|
| Diluted EPS |
—
|
-0.21
-75.0%
|
-0.12
+52.0%
|
-0.25
|
-0.15
-140.5%
|
0.37
+317.6%
|
-0.17
-21.4%
|
-0.14
+60.0%
|
-0.35
-400.0%
|
-0.07
+86.8%
|
-0.53
|
| Weighted average shares, basic |
—
|
—
|
33
+0.0%
|
33
|
27
+11.8%
|
24
+18.5%
|
20
+16.6%
|
17
+27.5%
|
14
+7.0%
|
13
+1.7%
|
12
|
| Weighted average shares, diluted |
—
|
33
+0.0%
|
33
+0.0%
|
33
|
27
+5.3%
|
25
+25.8%
|
20
+16.6%
|
17
+27.5%
|
14
+7.0%
|
13
+1.7%
|
12
|
| Other measures | |||||||||||
| Depreciation and amortization |
—
|
0
-49.3%
|
0
-22.8%
|
0
|
1
+14.6%
|
1
-3.7%
|
1
+54.5%
|
1
+6.5%
|
1
+67.3%
|
0
|
—
|
| EBITDA |
—
|
-3
-111.5%
|
-1
+47.0%
|
-2
|
-3
-460.8%
|
1
+188.9%
|
-1
-9.1%
|
-1
-115.7%
|
-0
-1529.0%
|
0
|
—
|
| Interest coverage |
—
|
-0.57x
|
-0.39x
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
| Margins | |||||||||||
| Operating margin |
-135.06%
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
-93.29%
|
-23.94%
|
-484.52%
|
| Pretax margin |
-478.25%
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
-448.68%
|
-77.28%
|
-503.32%
|
| Profit margin |
-478.25%
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
-448.68%
|
-75.29%
|
-502.87%
|
| EBITDA margin |
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
-43.83%
|
2.77%
|
—
|
How these figures are calculated
Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except per-share amounts and margins. Weighted average shares are in millions. Interest expense and finance costs are positive costs. A negative amount on a gain (loss) or income (expense) line is a loss or an expense. EBITDA is operating income plus depreciation and amortization. Interest coverage is operating income divided by interest expense. The first column is the trailing twelve months through the latest quarter. More on our methodology.
New to this? Read How to Read an Income Statement, With a Real Example.
Company profile
- Industry
- Services-Medical Laboratories (SIC 8071)
- Listed as
- FCHS (OTC)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Melbourne, FL
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1416876
- Former names
- Medical Billing Assistance, Inc. (until Mar 30, 2012); Medical Billing Assistance Inc (until Jan 3, 2011)
Other Services-Medical Laboratories companies
- Natera, Inc. NTRA
- Labcorp Holdings Inc. LH
- Quest Diagnostics Inc DGX
- Guardant Health, Inc. GH
- Caris Life Sciences, Inc. CAI
- GRAIL, Inc. GRAL
- RadNet, Inc. RDNT
- BillionToOne, Inc. BLLN
Source: SEC EDGAR filings. This is company-reported data, not investment advice.